These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 34464130)

  • 1. AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist of Retinoic Acid Receptor-Related Orphan Receptor C2.
    Narjes F; Llinas A; von Berg S; Jirholt J; Lever S; Pehrson R; Collins M; Malmberg A; Svanberg P; Xue Y; Olsson RI; Malmberg J; Hughes G; Hossain N; Grindebacke H; Leffler A; Krutrök N; Bäck E; Ramnegård M; Lepistö M; Thunberg L; Aagaard A; McPheat J; Hansson EL; Chen R; Xiong Y; Hansson TG
    J Med Chem; 2021 Sep; 64(18):13807-13829. PubMed ID: 34464130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 2H-chromone-4-one based sulfonamide derivatives as potent retinoic acid receptor-related orphan receptor γt inverse agonists.
    Chen L; Su M; Wu XZ; Wang DZ; Kang YY; Wang CG; Assani I; Wang MX; Zhao SF; Lv SM; Wang JW; Sun B; Li Y; Jin Q; Huang RZ; Liao ZX
    Eur J Med Chem; 2022 Feb; 229():114065. PubMed ID: 34971876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Drug with Lipophilicity-Dependent Potency Can Be Metabolically Stable: Discovery of a Potent and Selective Retinoic Acid Receptor-Related Orphan Receptor C2 (RORC2) Inverse Agonist as an Orally Bioavailable Anti-Inflammatory Agent.
    Wang Y; Liu H
    J Med Chem; 2018 Dec; 61(23):10412-10414. PubMed ID: 30507131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist.
    Schnute ME; Wennerstål M; Alley J; Bengtsson M; Blinn JR; Bolten CW; Braden T; Bonn T; Carlsson B; Caspers N; Chen M; Choi C; Collis LP; Crouse K; Färnegårdh M; Fennell KF; Fish S; Flick AC; Goos-Nilsson A; Gullberg H; Harris PK; Heasley SE; Hegen M; Hromockyj AE; Hu X; Husman B; Janosik T; Jones P; Kaila N; Kallin E; Kauppi B; Kiefer JR; Knafels J; Koehler K; Kruger L; Kurumbail RG; Kyne RE; Li W; Löfstedt J; Long SA; Menard CA; Mente S; Messing D; Meyers MJ; Napierata L; Nöteberg D; Nuhant P; Pelc MJ; Prinsen MJ; Rhönnstad P; Backström-Rydin E; Sandberg J; Sandström M; Shah F; Sjöberg M; Sundell A; Taylor AP; Thorarensen A; Trujillo JI; Trzupek JD; Unwalla R; Vajdos FF; Weinberg RA; Wood DC; Xing L; Zamaratski E; Zapf CW; Zhao Y; Wilhelmsson A; Berstein G
    J Med Chem; 2018 Dec; 61(23):10415-10439. PubMed ID: 30130103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of N-(2-benzyl-4-oxochroman-7-yl)-2-(5-(ethylsulfonyl) pyridin-2-yl) acetamide (b12) as a potent, selective, and orally available novel retinoic acid receptor-related orphan receptor γt inverse agonist.
    Chen L; Su M; Jin Q; Wang CG; Assani I; Wang MX; Zhao SF; Lv SM; Wang JW; Sun B; Li Y; Liao ZX
    Bioorg Chem; 2022 Feb; 119():105483. PubMed ID: 34906860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 1-{4-[3-fluoro-4-((3s,6r)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone (GNE-3500): a potent, selective, and orally bioavailable retinoic acid receptor-related orphan receptor C (RORc or RORγ) inverse agonist.
    Fauber BP; René O; Deng Y; DeVoss J; Eidenschenk C; Everett C; Ganguli A; Gobbi A; Hawkins J; Johnson AR; La H; Lesch J; Lockey P; Norman M; Ouyang W; Summerhill S; Wong H
    J Med Chem; 2015 Jul; 58(13):5308-22. PubMed ID: 26061388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tricyclic sulfones as potent, selective and efficacious RORγt inverse agonists - Exploring C6 and C8 SAR using late-stage functionalization.
    Shi Q; Xiao Z; Yang MG; Marcoux D; Cherney RJ; Yip S; Li P; Wu DR; Weigelt CA; Sack J; Khan J; Ruzanov M; Wang J; Yarde M; Ellen Cvijic M; Li S; Shuster DJ; Xie J; Sherry T; Obermeier M; Fura A; Stefanski K; Cornelius G; Chacko S; Shu YZ; Khandelwal P; Hynes J; Tino JA; Salter-Cid L; Denton R; Zhao Q; Dhar TGM
    Bioorg Med Chem Lett; 2020 Dec; 30(23):127521. PubMed ID: 32882417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534.
    Xue X; De Leon-Tabaldo A; Luna-Roman R; Castro G; Albers M; Schoetens F; DePrimo S; Devineni D; Wilde T; Goldberg S; Kinzel O; Hoffmann T; Fourie AM; Thurmond RL
    Sci Rep; 2021 May; 11(1):11066. PubMed ID: 34040108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of [ cis-3-({(5 R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1 H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5 H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist.
    Kono M; Ochida A; Oda T; Imada T; Banno Y; Taya N; Masada S; Kawamoto T; Yonemori K; Nara Y; Fukase Y; Yukawa T; Tokuhara H; Skene R; Sang BC; Hoffman ID; Snell GP; Uga K; Shibata A; Igaki K; Nakamura Y; Nakagawa H; Tsuchimori N; Yamasaki M; Shirai J; Yamamoto S
    J Med Chem; 2018 Apr; 61(7):2973-2988. PubMed ID: 29510038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, pharmacodynamics and safety of the inverse retinoic acid-related orphan receptor γ agonist AZD0284.
    Asimus S; Palmér R; Albayaty M; Forsman H; Lundin C; Olsson M; Pehrson R; Mo J; Russell M; Carlert S; Close D; Keeling D
    Br J Clin Pharmacol; 2020 Jul; 86(7):1398-1405. PubMed ID: 32067249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonists.
    Lu Z; Duan JJ; Xiao H; Neels J; Wu DR; Weigelt CA; Sack JS; Khan J; Ruzanov M; An Y; Yarde M; Karmakar A; Vishwakrishnan S; Baratam V; Shankarappa H; Vanteru S; Babu V; Basha M; Kumar Gupta A; Kumaravel S; Mathur A; Zhao Q; Salter-Cid LM; Carter PH; Murali Dhar TG
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2265-2269. PubMed ID: 31257087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel triazine derivatives as potent retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists.
    Lu L; Chen S; Yu M; Zhou R; Guo S; Chen JA; Wang H; Chen S; Luo C; Xie Q; Wang Y
    Eur J Med Chem; 2023 Aug; 256():115424. PubMed ID: 37167779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and Optimization of a Series of Sulfonamide Inverse Agonists for the Retinoic Acid Receptor-Related Orphan Receptor-α.
    Doebelin C; He Y; Campbell S; Nuhant P; Kumar N; Koenig M; Garcia-Ordonez R; Chang MR; Roush WR; Lin L; Kahn S; Cameron MD; Griffin PR; Solt LA; Kamenecka TM
    Med Chem; 2019; 15(6):676-684. PubMed ID: 30799793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel quinazolinedione derivatives as RORγt inverse agonist.
    Fukase Y; Sato A; Tomata Y; Ochida A; Kono M; Yonemori K; Koga K; Okui T; Yamasaki M; Fujitani Y; Nakagawa H; Koyama R; Nakayama M; Skene R; Sang BC; Hoffman I; Shirai J; Yamamoto S
    Bioorg Med Chem; 2018 Feb; 26(3):721-736. PubMed ID: 29342416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic inhibition of RORγt regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo.
    Skepner J; Ramesh R; Trocha M; Schmidt D; Baloglu E; Lobera M; Carlson T; Hill J; Orband-Miller LA; Barnes A; Boudjelal M; Sundrud M; Ghosh S; Yang J
    J Immunol; 2014 Mar; 192(6):2564-75. PubMed ID: 24516202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel N-sulfonamide-tetrahydroquinolines as potent retinoic acid receptor-related orphan receptor γt inverse agonists for the treatment of autoimmune diseases.
    Sun N; Ma X; Zhou K; Zhu C; Cao Z; Wang Y; Xu J; Fu W
    Eur J Med Chem; 2020 Feb; 187():111984. PubMed ID: 31881455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological inhibitory profile of TAK-828F, a potent and selective orally available RORγt inverse agonist.
    Shibata A; Uga K; Sato T; Sagara M; Igaki K; Nakamura Y; Ochida A; Kono M; Shirai J; Yamamoto S; Yamasaki M; Tsuchimori N
    Biochem Pharmacol; 2018 Apr; 150():35-45. PubMed ID: 29369782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt.
    Gege C; Albers M; Kinzel O; Kleymann G; Schlüter T; Steeneck C; Hoffmann T; Xue X; Cummings MD; Spurlino J; Milligan C; Fourie AM; Edwards JP; Leonard K; Coe K; Scott B; Pippel D; Goldberg SD
    Bioorg Med Chem Lett; 2020 Jun; 30(12):127205. PubMed ID: 32336498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Potent and Orally Bioavailable Inverse Agonists of the Retinoic Acid Receptor-Related Orphan Receptor C2.
    von Berg S; Xue Y; Collins M; Llinas A; Olsson RI; Halvarsson T; Lindskog M; Malmberg J; Jirholt J; Krutrök N; Ramnegård M; Brännström M; Lundqvist A; Lepistö M; Aagaard A; McPheat J; Hansson EL; Chen R; Xiong Y; Hansson TG; Narjes F
    ACS Med Chem Lett; 2019 Jun; 10(6):972-977. PubMed ID: 31223457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Chromane-6-Sulfonamide Derivative as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist.
    Chen L; Su M; Jin Q; Wang W; Wang CG; Assani I; Wang MX; Zhao SF; Lv SM; Wang JW; Sun B; Li Y; Liao ZX
    J Med Chem; 2021 Nov; 64(21):16106-16131. PubMed ID: 34723528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.